Jarvik Defends Role In Pfizer Ads
NJ.com Robert Jarvik, the inventor of the artificial heart, is defending his role in an ad campaign for Pfizer’s Lipitor that was yanked from the air as the result of a congressional probe into whether it was … via MediaPost Publications
Jarvik Defends Role In Pfizer Ads
NJ.com Robert Jarvik, the inventor of the artificial heart, is defending his role in an ad campaign for Pfizer’s Lipitor that was yanked from the air as the result of a congressional probe into whether it was … via MediaPost Publications
Lilly prepares for Alaska court fight
“If they lose the Alaska case in a big way, you can see a ripple effect in other cases, with other states getting more aggressive”
After trying for years to bat down claims that it misled doctors and patients about the side effects of its top-selling drug, Eli Lilly and Co. via IndyStar.com
Lilly knocked back by FDA on Zyprexa for schizophrenia treatment
“We are disappointed by the FDA’s decision and we are committed to ongoing discussions to better understand the agency’s perspective regarding this recent case of excessive sedation and to define the path forward and the associated timeline”
Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection for the treatment and maintenance treatment of schizophrenia in adults, … via News-Medical.Net
New Study of Targeted Therapies for Breast Cancer Establishes Model for Global Clinical Trials
BETHESDA, Md., Feb. 29, 2008- Two targeted medications
designed to treat an aggressive form of breast cancer are being
tested in a new study involving 8,000 participants in 50 countries
across six continents — a clinical trial that…
QPS Closes Acquisition of Bio-Kinetic Clinical Applications
NEWARK, Del. & SPRINGFIELD, Mo.–(BUSINESS WIRE)–Feb 28, 2008
- QPS, LLC, a leading full-service GLP-compliant contract research
organization providing testing services to support pre-clinical and
clinical research and development, announced…
Pharmacyclics Realigns to Focus on Advancing Expanded Pipeline of Promising Product Candidates
SUNNYVALE, Calif., February 28, 2008 /PRNewswire-FirstCall/ –
Pharmacyclics, Inc. today announced a corporate realignment to
reduce expenses and focus its activities on advancing its expanded
pipeline of promising new product candidates that…
Overweight Hispanic Kids Show Early Markers for Diabetes
“They are already exhibiting problems with circulation. There is an inflammatory process going on in the vessels”
A small U.S. study found that obese Hispanic children and adolescents with normal blood sugar levels had elevated markers for blood vessel inflammation that may put them at risk for both type 2 diabetes and … via Health Resources
Interpublic Announces Fourth Quarter and Full-Year 2007 Results
Significant improvement in profitability driven by organic
revenue growth and cost control
Net income applicable to common stockholders swings to $131.3
million for full-year 2007 from loss of ($79.3) million in
2006
Company achieves compliance…
Generic Drugs Slow Rise in Prescription Drug Costs, Saving $5.2 Billion in 2007
ST. LOUIS–(BUSINESS WIRE)–Feb 29, 2008 - Greater use of generic
drugs dramatically slowed the growth in prescription drug costs
during 2007, saving an estimated $5.2 billion for commercially
insured Americans and benefit plan sponsors.
During…